Market Overview

UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence

Share:
Related PCYC
Stocks That Battle Cancer Were The Best-Performing Biotechs In January
10 Biotech Stories You Might've Missed This Week
Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog (Zacks)

Dawson James initiated coverage on Pharmacyclics (NASDAQ: PCYC) with a Market Outperform rating and a $101 price target.

Dawson James commented, "Ibrutinib – a novel Btk inhibitor - represents the most exciting compound in the field of the multi-billion dollar market for B-cell related malignancies. Ibrutinib is, by far, the leader in this therapeutic category, easily has blockbuster potential and, based upon our analysis, is likely to elevate PCYC valuation to the very top-tier of biotech stocks. We believe the upcoming American Society Hematology meeting (ASH, December 7-12, Atlanta, GA) will further differentiate ibrutinib from any potential competitors."

Pharmacyclics closed at $55.01 on Thursday.

Latest Ratings for PCYC

DateFirmActionFromTo
Jan 2015JMP SecuritiesMaintainsMarket Outperform
Jan 2015CitigroupMaintainsBuy
Jan 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (PCYC)

Around the Web, We're Loving...

Get Benzinga's Newsletters